Key result
CK-2127107 significantly increased tibialis anterior muscle response to nerve activation compared to placebo, with the largest increase in peak force being ~60% at 10 Hz.
Why the study?
Does single doses of CK-2127107 (CK-107) improve force-frequency response of muscle in healthy participants?
Population
Healthy participants
Comparison
Single doses of CK-2127107 (CK-107) vs Placebo
Design
RCT, randomized, 4-period, crossover, double-blind
Authors
Loading...
Supports development for muscle impairment; extends preclinical data to humans.
RCT
double-blind
randomized
Does single doses of CK-2127107 (CK-107) improve force-frequency response of muscle in healthy participants?
Effect estimate: ~60% increase
CK-2127107 significantly amplifies the force-frequency response of skeletal muscle in healthy humans, supporting its potential development for patients with impaired muscle function.
Andrews et al. (2017) conducted an RCT in Healthy participants. CK-2127107 (CK-107) vs. placebo was evaluated on force-frequency response of foot dorsiflexion following stimulation of the deep fibular nerve to activate the tibialis anterior muscle (~60% increase). CK-2127107 significantly increased tibialis anterior muscle response to nerve activation compared to placebo, with the largest increase in peak force being ~60% at 10 Hz.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: